Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Ophthalmology

 

Booster blunder puts staff at risk

The Indian government's slowness to approve booster shots is putting lives at risk - particularly those of front line medical staff whose immunity is waning. HBI speaks to a disappointed operator source in the country to find out more.

Fresenius Helios expands in Colombia

Quironsalud, the Spanish arm of Fresenus Helios has expanded its Colombian business with the acquisition of Centro Oncológico de Antioquia and ophthalmology centre Clínica Clofán. In its nine month results Fresenius stated that Latin America were strong and "notably above expectations." We look at a booming market where Fresenius Helios spent the lion's share of its €770m on M&A deals in 2020 and 2019 alone.

“Secret” Artemis sale talks, as Veonet process progresses

HBI understands that Montagu, owners of Artemis Augenkliniken which is Germany’s second-largest ophthalmology chain by revenue, is in bilateral talks to sell. HBI names the potential buyer, and also has a delve into the ongoing sale - and current finances - of Veonet Group.

Opportunities abound in France’s new budget

France has committed to reforms in homecare, optometry, and mental health in its social security budget for next year. One source says that it's a particularly important budget with elections coming in the Spring of next year. Meanwhile, President Macron has also committed to replicating Germany's model for reimbursing digital health apps.

HBI 2021: Don’t cede your brand in internationalisation

Some revered global brands have become unstuck in their internationalisation by ceding control of a brand without any quality assurance. Panellists at HBI 2021 discussed how to manage that process more effectively. 

Ophthalmology: Sector Analysis

This vast unconsolidated sector offers huge opportunities particularly in the treatment of presbyopia and the growth of outsourcing. A panel of operators unpackage how they view the sector across EMEA and beyond. Confirmed speakers include: Dr Markus Hamm, OSG Johanna Öberg, Memira Eyecentre Paul Tomasic, Houlihan Lokey Ulla Napankangas, Coronaria Eye Health Chaired by: Tobias Koester, […]

Nordic launches a process for €2bn+ Veonet

Strong rumours reported by HBI back in July that Nordic Capital-backed ophthalmology group Veonet (including Germany's largest operator by revenue Ober Scharrer) would come to market before the autumn have been proven correct. HBI understands the group has launched a process, and a price tag of in excess of €2bn is expected.

Small-mid market M&A round up

As expected, M&A deal flow slowed through August as bankers and executives headed out on summer vacations. HBI has caught up with the mid-to-small-cap deals you may have missed; featuring hospitals, ophthalmology, and homecare. 

Find Us